Press release archive - GSK
Find out the latest news and updates from GSK, a global healthcare company, on its products, vaccines, medicines and research. Browse the press releases by date range and download the PDF files for more details.
Press releases | GSK US
Find the latest news and announcements from GSK US, a global healthcare company. Browse press releases by category, date range, or keyword, such as vaccines, medicines, lawsuits, awards, and more.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · AREXVY is the first RSV vaccine for adults 60 and older, based on data from a phase III trial that showed 82.6% efficacy against lower respiratory tract disease. The vaccine is expected to launch in the US before the 2023/24 RSV season and is …
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Find out the latest news and updates on GSK plc (GSK), a global pharmaceutical company. Read about its Zantac settlement, depemokimab trial, RSV vaccine, and more.
GSK lifts annual forecasts again, powered by strong vaccine launch
Nov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
FDA Approves GSK's New Blood Cancer Treatment - Bloomberg
Sep 15, 2023 · The US Food and Drug Administration cleared a new treatment from GlaxoSmithKline Plc for a rare blood cancer, bolstering the UK pharmaceutical company’s push back into oncology.
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
LONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK delivers strong 2022 performance with full year sales of £29.3 ...
Feb 1, 2023 · GSK reports sales of £29.3 billion, up 19% AER, and adjusted EPS of 139.7p, up 27% AER, for 2022. The company also announces its outlooks, pipeline, and R&D progress for 2023 and beyond.
For media and investors only - GSK
Jun 23, 2021 · New GSK will focus on Vaccines and Specialty Medicines, with a late-stage pipeline that could generate £20 billion in peak sales. The company expects to grow sales more than 5% and adjusted operating profit more than 10% CAGR 2021-26, and aims to deliver £33 billion sales by 2031.
GlaxoSmithKline PLC. - The New York Times
News about GlaxoSmithKline PLC., including commentary and archival articles published in The New York Times.